Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Eszopiclone

FDA-approved product (tablet, oral), marketed as Eszopiclone, Lunesta.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Eszopiclone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Insomnia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Benzodiazepine related drugs
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae32.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Eszopiclone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Eszopiclone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Grain Moxibustion Treatment on Insomnia: a Randomized Controlled Trial

    NCT04980703 · start 2027-07-01

    Registered record
    Registry ID
    NCT04980703
    Conditions
    Sleep Initiation and Maintenance Disorders
    Interventions
    Grain moxibustion; Sham grain moxibustion; Standard care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2027-07-01
    Completion
    2029-07-31
    Enrolment
    102

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSleep Initiation and Maintenance Disorders
    InterventionGrain moxibustion; Sham grain moxibustion; Standard care
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Endotypic Traits and Obstructive Sleep Apnea Surgery

    NCT05953610 · start 2024-01-07

    Registered record
    Registry ID
    NCT05953610
    Conditions
    Obstructive Sleep Apnea
    Interventions
    Acetazolamide 500 MG QHS; Eszopiclone 3 mg QHS
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-01-07
    Completion
    2028-08-31
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObstructive Sleep Apnea
    InterventionAcetazolamide 500 MG QHS; Eszopiclone 3 mg QHS
    PhasePhase 2
    Registry statusRecruiting

  • Rescue Pharmacotherapy for OSA

    NCT05293600 · start 2023-07-01

    Registered record
    Registry ID
    NCT05293600
    Conditions
    Obstructive Sleep Apnea
    Interventions
    Placebo; Acetazolamide; Trazodone; Atomoxetine and eszopiclone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2023-07-01
    Completion
    2026-10-30
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObstructive Sleep Apnea
    InterventionPlacebo; Acetazolamide; Trazodone; Atomoxetine and eszopiclone
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Bioavailability of Eszopiclone 3.0 mg With Regards to Reference Product

    NCT05349396 · start 2022-04-11

    Registered record
    Registry ID
    NCT05349396
    Conditions
    Bioequivalence
    Interventions
    Eszopiclone 3mg Test Drug T-1 Coated Tablets; Eszopiclone 3mg Test Drug T-2 Coated Tablets; Eszopiclone 3mg Reference Product Coated Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-04-11
    Completion
    2022-04-19
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBioequivalence
    InterventionEszopiclone 3mg Test Drug T-1 Coated Tablets; Eszopiclone 3mg Test Drug T-2 Coated Tablets; Eszopiclone 3mg Reference Product Coated Tablets
    PhasePhase 1
    Registry statusCompleted

  • National Adaptive Trial for PTSD Related Insomnia

    NCT03668041 · start 2021-02-25

    Registered record
    Registry ID
    NCT03668041
    Conditions
    Insomnia
    Interventions
    Trazodone; Eszopiclone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-02-25
    Completion
    2026-03-30
    Enrolment
    673

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia
    InterventionTrazodone; Eszopiclone; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of Chronic Hypnotic Use 2

    NCT02456532 · start 2015-08-05

    Registered record
    Registry ID
    NCT02456532
    Conditions
    Chronic Insomnia
    Interventions
    placebo; Zolpidem CR; Eszopiclone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-08-05
    Completion
    2022-02-22
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Insomnia
    Interventionplacebo; Zolpidem CR; Eszopiclone
    PhasePhase 4
    Registry statusCompleted

  • Investigation of the Safety and Efficacy of Long Term Administration of Eszopiclone in Insomnia Patients

    NCT02455271 · start 2012-10-01

    Registered record
    Registry ID
    NCT02455271
    Conditions
    Insomnia
    Interventions
    Eszopiclone
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-10-01
    Completion
    2015-12-22
    Enrolment
    438

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia
    InterventionEszopiclone
    PhaseNot recorded
    Registry statusCompleted

  • Sleep Effectiveness and Insulin and Glucose Homeostasis

    NCT01887691 · start 2012-10

    Registered record
    Registry ID
    NCT01887691
    Conditions
    Diabetes; Prediabetic; Prediabetes; Glucose Intolerance
    Interventions
    eszopiclone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2012-10
    Completion
    2019-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes; Prediabetic; Prediabetes; Glucose Intolerance
    Interventioneszopiclone
    PhasePhase 1
    Registry statusTerminated

  • Combination Therapy to Treat Sleep Apnea

    NCT01633827 · start 2012-08

    Registered record
    Registry ID
    NCT01633827
    Conditions
    Sleep Apnea, Obstructive
    Interventions
    Placebo pill; Sedative; Room air; Oxygen
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-08
    Completion
    2014-12
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSleep Apnea, Obstructive
    InterventionPlacebo pill; Sedative; Room air; Oxygen
    PhaseNot applicable
    Registry statusCompleted

  • Eszopiclone for the Treatment of Posttraumatic Stress Disorder

    NCT01605253 · start 2012-03

    Registered record
    Registry ID
    NCT01605253
    Conditions
    Posttraumatic Stress Disorders
    Interventions
    Eszopiclone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-03
    Completion
    2015-12
    Enrolment
    81

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPosttraumatic Stress Disorders
    InterventionEszopiclone; Placebo
    PhasePhase 4
    Registry statusCompleted

  • A Non-inferiority Study With Two Treatment Arms Eszopiclone 3 mg Versus Zopiclone 7.5 mg - for the Treatment of Insomnia

    NCT01100164 · start 2011-03

    Registered record
    Registry ID
    NCT01100164
    Conditions
    INSOMNIA
    Interventions
    Eszopiclone; Zopiclone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-03
    Completion
    2012-04
    Enrolment
    263

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionINSOMNIA
    InterventionEszopiclone; Zopiclone
    PhasePhase 3
    Registry statusCompleted

  • A Bioequivalence and Food Effect Study of SEP-190 in Japanese Healthy Subjects (Study SEP 190-102)

    NCT01055834 · start 2010-01

    Registered record
    Registry ID
    NCT01055834
    Conditions
    Insomnia
    Interventions
    Eszopiclone 3 mg; Eszopiclone 1 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-01
    Completion
    2010-02
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia
    InterventionEszopiclone 3 mg; Eszopiclone 1 mg
    PhasePhase 1
    Registry statusCompleted

  • Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia

    NCT00856973 · start 2009-05

    Registered record
    Registry ID
    NCT00856973
    Conditions
    Insomnia; Attention Deficit Hyperactivity Disorder
    Interventions
    eszopiclone; eszopiclone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-05
    Completion
    2011-07
    Enrolment
    486

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia; Attention Deficit Hyperactivity Disorder
    Interventioneszopiclone; eszopiclone; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia

    NCT00857220 · start 2009-05

    Registered record
    Registry ID
    NCT00857220
    Conditions
    Insomnia; Attention Deficit Hyperactivity Disorder
    Interventions
    eszopiclone; eszopiclone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-05
    Completion
    2011-10
    Enrolment
    304

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia; Attention Deficit Hyperactivity Disorder
    Interventioneszopiclone; eszopiclone
    PhasePhase 3
    Registry statusCompleted

  • Effects of Daytime Eszopiclone Administration in Shift Workers

    NCT00900159 · start 2009-05

    Registered record
    Registry ID
    NCT00900159
    Conditions
    Shift-Work Sleep Disorder
    Interventions
    eszopiclone; matching placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-05
    Completion
    2010-02
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionShift-Work Sleep Disorder
    Interventioneszopiclone; matching placebo
    PhaseNot applicable
    Registry statusCompleted